Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VT EBV

Next Previous
Drug Profile

VT EBV

Alternative Names: EBV-CTL - ViGenCell; Epstein-barr virus human cytotoxic T lymphocytes; VT-EBV; VT-EBV-H; VT-EBV-N; VT-EBV-P

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViGenCell
  • Developer Catholic University of Korea; ViGenCell
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Extranodal NK-T-cell lymphoma; Lymphoma
  • No development reported Lymphoproliferative disorders
  • Discontinued Head and neck cancer

Most Recent Events

  • 29 May 2026 Efficacy and adverse events data from a phase II trial in Eextranodal NK cell lymphoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 26 Jul 2022 Phase II development is still ongoing for Extranodal NK-T-cell lymphoma and Lymphoma in South Korea (ViGenCell pipeline, July 2022)
  • 26 Jul 2022 Discontinued for Head and neck cancer in South Korea (IV) before July 2022 (ViGenCell pipeline, July 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top